Related Experiment Video
Updated: Mar 14, 2026

HPLC Coupled with Chemical Fingerprinting for Multi-Pattern Recognition for Identifying the Authenticity of Clematidis Armandii Caulis
Published on: November 11, 2022
Invalidation of Atorvastatin Patent Highlights Complex Chinese Patent Law
Feng-Chi Chen1, Kuo-Liang Yeh2
1Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan 350; Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan 300; School of Dentistry, China Medical University, Taichung, Taiwan 404.
Abstract:
Pfizer's atorvastatin (Lipitor) is a blockbuster drug for the treatment of cardiovascular diseases. In China, a critical polymorph patent of this drug has been recently invalidated by the Supreme People's Court for insufficiency of disclosure. Here, we discuss the particularities in patent litigation in China worth attention from the community.
Related Concept Videos
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Bioequivalence studies: Biowaivers
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Clinically Relevant Drug Product Specifications: Methods of Establishment

